

September 1, 2017

Sumitomo Dainippon Pharma Co., Ltd.

## **Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced that the following organizational realignment and Changes in the posts assumed by Executive Officers and other key positions, effective October 1, 2017:

### **I. Organizational Realignment (effective October 1, 2017)**

#### **Drug Research (Division)**

1. Drug Research Division is renamed (in Japanese language only).
2. Research Planning & Intelligence is renamed to Research Planning & Coordination.
3. Research Administration is dissolved and its functions are transferred to Research Planning & Coordination and Corporate Service Center.
4. Innovative Drug Discovery Laboratories and Drug Development Research Laboratories are reorganized into Pharmacology Research Unit and Chemistry Research Unit.
5. Preclinical Research Laboratories is renamed to Preclinical Research Unit.
6. Platform Technology Research Unit is created.

Sumitomo Dainippon Pharma will apply a “Project-based Research Management System” by appointing Project Leaders and Project Directors in the Drug Research Division, which is the highlight of this renaming/reorganizing, to strongly accelerate the drug discovery research projects. Project Leaders are primarily responsible for advancing the drug discovery research projects they are in charge of, while the Project Directors are responsible for strategic proposal regarding conceptual ideas of new research programs and enrichment of research portfolio in Drug Research Division as a whole.

The Drug Research Division will work as one team to effectively maximize the research outcomes, advancing the drug discovery research projects and increasing the research success rate. The Project Leaders will take the initiative in such research team efforts.

#### **Drug Development (Division)**

1. Project Management is renamed to Development Planning & Management.
2. Development Administration is dissolved.
3. Development Regulatory Affairs is created.

## II. Changes in Executive Officers

Changes in the posts assumed by Executive Officers (effective October 1, 2017)

Post as of October 1, 2017	Current post	Name
Member, Board of Directors, Executive Officer Senior Executive Research Director, Drug Research Division Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center	Member, Board of Directors, Executive Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Drug Research Division	Toru Kimura
Executive Officer Executive Research Director, Drug Research Division	Executive Officer Executive Director, Drug Research Division	Hideyuki Harada

## III. Changes in Personnel (effective October 1, 2017)

Corporate Departments

Position as of October 1, 2017	Current position	Name
Senior Strategic Officer – North America non-oncology business	Senior Strategic Officer – International business	Shinichiro Katayanagi
Deputy Senior Director, Corporate Service Center	Senior Director, Research Administration	Masashi Yabuki

Drug Research (Division)

Position as of October 1, 2017	Current position	Name
Project Director, Early-phase Drug Research	Senior Director, External Innovation Development Office	Masakazu Hashimoto
Project Director, Late-phase Drug Research	Senior Director, Innovative Drug Discovery Laboratories	Takeo Ishiyama
Senior Director, Research Planning & Coordination	Senior Director, Research Planning & Intelligence	Setsuko Yamamoto
Senior Director, External Innovation Development Office	Senior Director, Drug Development Research Laboratories	Isao Shimizu
Senior Director, Pharmacology Research Unit	Director, Innovative Drug Discovery Research Management Group, Innovative Drug Discovery Laboratories	Michiko Ono

Senior Director, Chemistry Research Unit	Director, Drug Development Chemistry Group I, Drug Development Research Laboratories	Katsunori Tsuboi
Senior Director, Preclinical Research Unit	Senior Director, Preclinical Research Laboratories	Kiyoko Bando
Senior Director, Platform Technology Research Unit Senior Director, Genomic Science Laboratories	Senior Research Fellow, Molecular Pathophysiology Research	Hidetaka Nagata

#### Drug Development (Division)

Position as of October 1, 2017	Current position	Name
Senior Director, Development Planning & Management	Senior Director, Project Management	Teruya Murata
Senior Director, Development Regulatory Affairs Director, Development RA Group, Development Regulatory Affairs	Director, Development Regulatory Affairs Group, Clinical Research	Kenichi Otani

#### Sales & Marketing (Division)

Position as of October 1, 2017	Current position	Name
Deputy Executive Director, Sales & Marketing Division Senior Director, Sales & Marketing Management	Senior Director, Sales & Marketing Management	Takuya Taguchi
Senior Director, Distribution Management Director, Wholesaler Service Group, Distribution Management	Senior Director, Distribution Management	Toshinobu Shiina
Senior Director, Kita-Kanto Branch	Deputy Senior Director, Hospital Promotion, Kyushu Branch	Hiroshi Takaoka
Senior Director, Yokohama Branch	Deputy Senior Director, Hospital Promotion, Tokai Branch	Yasutoshi Araki
Deputy Senior Director, Hospital Promotion, Tokai Branch	Director, Osaka Psychiatry Group III, Hospital Promotion, Osaka Branch	Hidekatsu Kuroda
Senior Director, Keiji-Hokuriku Branch	Deputy Senior Director, Hospital Promotion, Osaka Branch	Takayuki Sato
Senior Director, Osaka Branch	Senior Director, Osaka Branch	Masaichi Fujimoto

Deputy Senior Director, Hospital Promotion, Osaka Branch		
Senior Director, Kyushu Branch Deputy Senior Director, Hospital Promotion, Kyushu Branch	Senior Director, Yokohama Branch	Koji Yamazaki

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)